Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;23(12):4317-26.
doi: 10.1096/fj.08-128801. Epub 2009 Aug 11.

Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways

Steven K Huang  1 , Eric S White, Scott H Wettlaufer, Heather Grifka, Cory M Hogaboam, Victor J Thannickal, Jeffrey C Horowitz, Marc Peters-Golden
Affiliations

Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways

Steven K Huang et al. FASEB J. 2009 Dec.

Abstract

Although the lipid mediator prostaglandin E(2) (PGE(2)) exerts antifibrotic effects by inhibiting multiple fibroblast functions, its ability to regulate fibroblast survival is unknown. Here, we examined the effects of this prostanoid on apoptosis and apoptosis pathways in normal and fibrotic lung fibroblasts. As compared to medium alone, 24 h of treatment with PGE(2) increased apoptosis of normal lung fibroblasts in a dose-dependent manner (EC(50) approximately 50 nM), as measured by annexin V staining, caspase 3 activity, cleavage of poly-ADP-ribose polymerase, and single-stranded DNA levels. PGE(2) also potentiated apoptosis elicited by Fas ligand plus cycloheximide. These proapoptotic actions were dependent on signaling through the EP2/EP4 receptors and by downstream activation of both caspases 8 and 9. Silencing and gene deletion of PTEN demonstrated that the effects of PGE(2) involved decreased activity of the prosurvival molecule Akt. PGE(2) also down-regulated expression of survivin, an inhibitor of apoptosis, and increased expression of Fas. Fibroblasts from patients with pulmonary fibrosis exhibited resistance to the apoptotic effects of PGE(2). These findings show for the first time that, in contrast to its effects on many other cell types, PGE(2) promotes apoptosis in lung fibroblasts through diverse pathways. They provide another dimension by which PGE(2) may inhibit, and perhaps even reverse, fibrogenesis in patients with interstitial lung disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PGE2 dose-dependently increases fibroblast apoptosis. IMR-90 fibroblasts were treated for 24 h with varying concentrations of PGE2 and apoptosis was measured by annexin V/PI staining (n=3) (A), caspase 3 activity (n=3) (B), cleavage of PARP (n=4) (C), and ssDNA levels (n=3) (D), as described in Materials and Methods. *P < 0.05 vs. untreated cells.
Figure 2.
Figure 2.
PGE2 potentiates FasL-induced apoptosis of fibroblasts. IMR-90 fibroblasts were treated in the presence or absence of PGE2 (0.1 μM) and FasL (100 ng/ml) plus CHX (0.5 μg/ml) for 24 h, and cellular apoptosis was measured by annexin V/PI staining (n=3). Results are expressed as the percentage of annexin V+/PI− (early apoptosis) cells. *P < 0.05.
Figure 3.
Figure 3.
PGE2 elicits apoptosis via EP2/EP4 signaling. IMR-90 cells were treated for 24 h with PGE2 (500 nM), the EP2-specific agonist butaprost free acid (BFA; 500 nM), the EP3-specific agonist ONO-AE3–248 (100 nM), or the EP4-specific agonist ONO-AE1–329 (100 nM), and apoptosis was measured by cleavage of PARP. Top panel: representative blot. Bottom panel: densitometric analysis of cleaved PARP relative to α-tubulin (n=3). *P < 0.05 vs. untreated control.
Figure 4.
Figure 4.
PGE2 promotes fibroblast apoptosis via both caspases 8 and 9. A) IMR-90 fibroblasts were treated with PGE2 (0.5 μM) in the presence or absence of the caspase 8 inhibitor Z-IETD-FMK (25 μM) or the caspase 9 inhibitor Z-LEHD-FMK (25 μM) for 24 h. Caspase 3 activity was measured as described in Materials and Methods; data are expressed as a percentage of activity relative to the no-PGE2 control (n=4). *P < 0.05. B) IMR-90 fibroblasts were treated with PGE2 (0.5 μM), Z-IETD-FMK (25 μM), and/or Z-LEHD-FMK (25 μM) for 24 h. Lysates were immunoblotted for cleaved PARP. Top panel: representative immunoblot. Bottom panel: densitometry of cleaved PARP normalized to α-tubulin (n=3).
Figure 5.
Figure 5.
Diminished capacity for PGE2-induced apoptosis in PTEN−/− fibroblasts. PTEN−/− and wild-type (wt) murine embryonic fibroblasts were treated for 24 h with PGE2 at the indicated concentrations. Phosphorylated Akt (A) and cleaved PARP (B) were assayed by immunoblot analysis. Top panels: representative immunoblots. Bottom panels: relative densitometry normalized to untreated controls (wt, n=3; PTEN−/−, n=4). *P < 0.05.
Figure 6.
Figure 6.
PTEN silencing diminishes PGE2-induced apoptosis in fibroblasts. A) PTEN expression was assayed by immunoblot in cells treated with control or PTEN siRNA for 48 h. Top panel: representative blot. Bottom panel: mean densitometric data (n=4). *P < 0.05. B) PTEN siRNA- and control siRNA-treated cells were exposed to PGE2 (0.1 μM) for 24 h, and cleaved PARP was assayed by immunoblot. Top panel: representative blot. Bottom panel: densitometry of cleaved PARP/α-tubulin (n=3). CPT (2 μg/ml) was used as a positive control. *P < 0.05 vs. no-PGE2 treatment.
Figure 7.
Figure 7.
PGE2 modulates fibroblast expression of survivin and Fas receptor. IMR-90 fibroblasts were treated for 24 h with the indicated concentrations of PGE2, and survivin expression (n=3) (A) and Fas receptor expression (n=3) (B) were determined by immunoblot analysis. *P < 0.05 vs. no-PGE2 treatment.
Figure 8.
Figure 8.
PGE2-induced apoptosis in adult control and UIP fibroblasts. A) Fibroblasts from the lungs of patients with UIP (n=8, white bars) and nonfibrotic controls (n=3, black bars) were treated with PGE2 for 24 h, and apoptosis was measured by annexin V/PI staining, with results expressed as the percentage of annexin V+/PI− (early apoptosis) cells. Responses of individual UIP lines are displayed at right, segregated within responsive and unresponsive groups. B) UIP (n=3) and nonfibrotic control (n=4) fibroblasts were treated with PGE2 (0.1 μM) ± FasL (100 ng/ml) + CHX (0.5 μg/ml) for 24 h. Cells were stained for annexin V and PI; percentage of annexin V+/PI− cells is shown.
Figure 9.
Figure 9.
Schema of PGE2-induced apoptosis in lung fibroblasts. PGE2, synthesized by the cyclooxygenase (COX) pathway, induces apoptosis by increasing PTEN activity and decreasing Akt activity. PGE2 also decreases survivin and increases Fas expression in lung fibroblasts. PGE2-induced apoptosis is mediated by ligation of the EP2 and EP4 receptors; relative contributions of EP2 and EP4 signaling to the 3 apoptosis pathways remain to be determined.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Danial N N, Korsmeyer S J. Cell death: critical control points. Cell. 2004;116:205–219. - PubMed
    1. Barbas-Filho J V, Ferreira M A, Sesso A, Kairalla R A, Carvalho C R, Capelozzi V L. Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP) J Clin Pathol. 2001;54:132–138. - PMC - PubMed
    1. Uhal B D, Joshi I, Hughes W F, Ramos C, Pardo A, Selman M. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol. 1998;275:L1192–L1199. - PubMed
    1. Plataki M, Koutsopoulos A V, Darivianaki K, Delides G, Siafakas N M, Bouros D. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest. 2005;127:266–274. - PubMed
    1. Selman M, King T E, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136–151. - PubMed

Publication types